Patent application number | Description | Published |
20080249068 | Method of Extending the Dose Range of Vitamin D Compounds - Inhibitors of bone calcium resorption are administered, and calcium intake in the subject's diet is restricted, to allow high doses of vitamin D compounds or mimetics to be given with the intent of treating diseases such as metabolic bone diseases, hyperparathyroidism, cancer, psoriasis, and autoimmune diseases without the dangers of calcification of kidney, heart, and aorta. Inhibitors of bone calcium resorption include the bis-phosphonates, OPG (osteoprotegerin) or the soluble RANKL (receptor activator of NF-κB ligand) receptor known as sRANK (soluble RANK which is the protein expressed by the NF-κB gene), and function to block the availability of calcium from bone thereby preventing hypercalcemia and the resulting calcification of soft tissues. Thus, high doses of 1α,25-dihydroxyvitamin D | 10-09-2008 |
20080261925 | COMPOUNDS, COMPOSITIONS, KITS AND METHODS OF USE TO ORALLY AND TOPICALLY TREAT ACNE AND OTHER SKIN CONDITIONS BY ADMINISTERING A 19-NOR CONTAINING VITAMIN D ANALOG WITH OR WITHOUT A RETINOID - Oral and topical pharmaceutical compositions, kits and methods of treatment thereof for treating various skin disorder including acne, psoriasis, ichthyosis, photoaging, photodamaged skin, and, skin cancer. Exemplary vitamin D analogs as active pharmaceutical ingredients include 2-methylene-19-nor-20(S)-1α-hydroxy-bishomopregnacalciferol, 19-nor-26,27-dimethylene-20(S)-2-methylene-1α,25-dihydroxyvitamin D | 10-23-2008 |
20080300223 | (20R)-2a-Methyl-19,26,27-Trinor-Vitamin D Analogs - This invention discloses (20R)-2α-methyl-19,26,27-trinor-vitamin D analogs, and specifically (20R)-2α-methyl-19,26,27-trinor-1α,25-dihydroxyvitamin D | 12-04-2008 |
20090004133 | Methods and compositions for phosphate binding - The present invention provides improved methods and compositions for therapeutically controlling and/or reducing serum phosphate levels in animals and mammalian patients. The methods comprise administering to the patient an amount of a dendrimer composition effective to prevent absorption of substantial amounts of phosphate from the patient's GI tract. In a preferred version, a dose of between 2.5 and 15 grams per day is effective to prevent over 80% of phosphate present in the patient's GI tract from being absorbed. The dendrimer composition may comprise a hydrocitrate, hydrochloride, hydrobromide, hydroacetate or hydroanionic form. | 01-01-2009 |
20090143342 | 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds - This invention provides a novel class of vitamin D related compounds, namely, the 2-alkylidene-19-nor-vitamin D derivatives, as well as a general method for their chemical synthesis. The compounds have the formula: | 06-04-2009 |
20090170818 | (20S)-23,23-Difluoro-Methylene-19-Nor-Bishomopregnacalciferol-Vitamin D Analogs - This invention discloses (20S)-23,23-difluoro-2-methylene-19-nor-bishomopregnacalciferol-vitamin D analogs, and specifically (20S)-23,23-difluoro-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol, and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also has little, if any, calcemic activity and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as renal osteodystrophy. This compound may also be used for the treatment or prevention of obesity. | 07-02-2009 |
20090170819 | (20R)-23,23-Difluoro-2-Methylene-19-Nor-Bishomopregnacalciferol-Vitamin D Analogs - This invention discloses (20R)-23,23-difluoro-2-methylene-19-nor-bishomopregnacalciferol-vitamin D analogs, and specifically (20R)-23,23-difluoro-1 α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol, and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also has little, if any, calcemic activity and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as renal osteodystrophy. This compound may also be used for the treatment or prevention of obesity. | 07-02-2009 |
20090170820 | 2-Methylene-(20S,25R)-19,26-Dinor-Vitamin D Analogs - This invention discloses 2-methylene-(20S,25R)-19,26-dinor-vitamin D analogs, and specifically 2-methylene-(20S,25R)-19,26-dinor-1α,25-dihydroxyvitamin D | 07-02-2009 |
20090170821 | 2-Methylene-(20S,25S)-19,26-Dinor-Vitamin D Analogs - This invention discloses 2-methylene-(20S,25S)-19,26-dinor-vitamin D analogs, and specifically 2-methylene-(20S,25S)-19,26-dinor-1α,25-dihydroxyvitamin D | 07-02-2009 |
20090170822 | 2-Methylene-20-Methyl-19,24,25,26,27-Pentanor-Vitamin D Analogs - This invention discloses 2-methylene-20-methyl-19,24,25,26,27-pentanor-vitamin D analogs, and specifically 2-methylene-20-methyl-1α-hydroxy-19,24,25,26,27-pentanor-vitamin D | 07-02-2009 |
20090186950 | 13,13-Dimethyl-des-C,D Analogs of 1Alpha,25-Dihydroxy-19-Nor-Vitamin D3 Compounds and Topical Composition Dosage Forms and Methods of Treating Skin Conditions Thereof - 13,13-Dimethyl-des-C,D analogs of 1α,25-dihydroxy-19-nor-vitamin D | 07-23-2009 |
20090281340 | 1ALPHA-HYDROXY-2-(3'-HYDROXYPROPYLIDENE)-19-NOR-VITAMIN D COMPOUNDS AND METHODS OF MAKING AND TREATMENT THEREOF - Disclosed are 1α-hydroxy-2-(3′-hydroxypropylidene)-19-nor-vitamin D compounds, pharmaceutical compositions, and methods of making and treatment thereof. The compounds are generally directed to biologically active 2-alkylidene-19-nor-vitamin D compounds and analogs thereof characterized by the presence of a 3′-hydroxypropylidene moiety at C-2 and the presence of an abbreviated alkyl side-chain free of any hydroxyl moiety. | 11-12-2009 |
20100009940 | 2-Methylene-(20E)-20(22)-Dehydro-19-Nor-Vitamin D Analogs - This invention discloses 2-methylene-(20E)-20(22)-dehydro-19-nor-vitamin D analogs, and specifically 2-methylene-(20E)-20(22)-dehydro-19-nor-1α,25-dihydroxyvitamin D | 01-14-2010 |
20100009941 | 2-Methylene-20(21)-Dehydro-19-Nor-Vitamin D Analogs - This invention discloses 2-methylene-20(21)-dehydro-19-nor-vitamin D analogs, and specifically 2-methylene-20(21)-dehydro-19-nor-1α,25-dihydroxyvitamin D | 01-14-2010 |
20100009942 | 2-Methylene-(17Z)-17(20)-Dehydro-19,21-Dinor-Vitamin D Analogs - This invention discloses 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-vitamin D analogs, and specifically 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-1α, 25-dihydroxyvitamin D | 01-14-2010 |
20100009943 | 2-Methylene-(22E)-25-(1-Methylene-Hexyl)-26,27-Cyclo-22-Dehydro-19-Nor-Vit- amin D Analogs - This invention discloses 2-methylene-(22E)-25-(1-methylene-hexyl)-26,27-cyclo-22-dehydro-19-nor-vitamin D analogs, and specifically 2-methylene-(22E)-25-(1-methylene-hexyl)-26,27-cyclo-22-dehydro-19-nor-1α,24(R)-dihydroxyvitamin D | 01-14-2010 |
20100009944 | 19-Nor-Vitamin D Analogs with 1,2-Dihydrofuran Ring - 19-nor-vitamin D analogs having an additional dihydrofuran ring connecting the 1α-oxygen and carbon-2 of the A-ring of the analog, and pharmaceutical uses therefore, are described. These compounds exhibit selective in vitro and in vivo activities, making them therapeutic agents for the treatment or prophylaxis of autoimmune diseases, some types of cancers, secondary hyperparathyroidism, psoriasis, or other skin diseases. | 01-14-2010 |
20100009945 | 19-NOR-VITAMIN D ANALOGS WITH 3,2-DIHYDROFURAN RING - 19-nor-vitamin D analogs having an additional dihydrofuran ring connecting the 3β-oxygen and carbon-2 of the A-ring of the analog, and pharmaceutical uses therefore, are described. These compounds exhibit selective in vitro and in vivo activities, making them therapeutic agents for the treatment or prophylaxis of autoimmune diseases, some types of cancers, metabolic bone diseases, osteomalacia, osteopenia, secondary hyperparathyroidism, psoriasis, or other skin diseases. | 01-14-2010 |
20100009946 | 2-Methylene-19,26-Dinor-(20R,22E,25R)-Vitamin D Analogs - This invention discloses 2-methylene-19,26-dinor-(20R,22E,25R)-vitamin D analogs, and specifically 2-methylene-19,26-dinor-(20R,22E,25R)-1α,25-dihydroxyvitamin D | 01-14-2010 |
20100009947 | 2-Methylene-19,26-Dinor-(20S,22E,25R)-Vitamin D Analogs - This invention discloses 2-methylene-19,26-dinor-(20S,22E,25R)-vitamin D analogs, and specifically 2-methylene-19,26-dinor-(20S,22E,25R)-1α,25-dihydroxyvitamin D | 01-14-2010 |
20100160267 | Treatment of Inflammatory Bowel Disease With 2-Methylene-19-Nor-Vitamin D Compounds - A method of preventing and/or treating inflammatory bowel disease, particularly ulcerative colitis and Crohn's disease, is disclosed. The method involves administering a 2-methylene-19-nor-vitamin D compound in an amount effective to treat the disease. The administration of a 2-methylene-19-nor-vitamin D compound also prevents the development of or delays the onset of inflammatory bowel disease in susceptible individuals. The preferred compounds are 1α-hydroxy-2-methylene-19-nor-homopregnacalciferol and 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D | 06-24-2010 |
20100179344 | 2-Alkylidene-18,19-Dinor-Vitamin D Compounds - 2-alkylidene-18,19-dinor-vitamin D compounds are disclosed as well as pharmaceutical uses for these compounds and methods of synthesizing these compounds. These compounds are characterized by low bone calcium mobilization activity and high intestinal calcium transport activity. This results in novel therapeutic agents for the treatment and prophylaxis of diseases where bone formation is desired, particularly osteoporosis, as well as autoimmune diseases such as multiple sclerosis, diabetes mellitus and lupus. These compounds also exhibit pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis. These compounds also increase both breaking strength and crushing strength of bones evidencing use in conjunction with bone replacement surgery such as hip and knee replacements. | 07-15-2010 |
20110003892 | ALL-TRANS RETINOID ESTERS AS ACTIVE PHARMACEUTICAL INGREDIENTS, ORAL AND TOPICAL DOSAGE FORM COMPOSITIONS THEREOF, AND METHODS OF TREATING SKIN CONDITIONS THEREOF - Active pharmaceutical ingredients being retinoic acid ester compounds including all- trans-retinoic acid tent-butyl ester, all-trans-retinoic acid iso-butyl ester, all-trans-retinoic acid iso-propyl ester, all-trans-retinoic acid sec-butyl ester, and, all-trans-retinoic acid 1-adamantyl ester, oral and topical dosage form compositions thereof, and methods of treating various skin conditions thereof. | 01-06-2011 |
20110034426 | Method of Preventing Renal Disease and Treating Symptoms Thereof - The invention relates to novel methods of using 2-methylene-19-nor-20(S)-1,25-dihydroxyvitamin D | 02-10-2011 |
20110059926 | Vitamin D Compounds and Methods for Reducing Ocular Hypertension (OHT) - The present invention relates to compounds and methods for reducing intraocular pressure and treating ocular hypertension in a subject. | 03-10-2011 |
20110059927 | Calcium Formate For Use As A Dietary Supplement - A calcium formate composition for oral administration to an individual for the purpose of supplementary dietary calcium is disclosed. | 03-10-2011 |
20110082121 | 1-Desoxy-2-Methylene-19-Nor-Vitamin D Analogs and Their Uses - This invention discloses 1-desoxy-2-methylene-19-nor-vitamin D analogs, and specifically (20S)-25-hydroxy-1-desoxy-2-methylene-19-nor-vitamin D | 04-07-2011 |
20110082122 | 19-Nor-Vitamin D Analogs With 1,2- or 3,2-Cyclopentene Ring - 19-nor-vitamin D analogs having an additional cyclopentene ring connecting carbon 1 and carbon 2, or connecting carbon 3 and carbon-2 of the A-ring of the analog, and pharmaceutical uses therefore, are described. These compounds exhibit selective in vitro activities, making them therapeutic agents for the treatment or prophylaxis of some types of cancers, particularly leukemia, colon cancer, breast cancer, skin cancer or prostate cancer. | 04-07-2011 |
20110082123 | 6-Methylvitamin D3 Analogs and Their Uses - This invention discloses 6-methylvitamin D | 04-07-2011 |
20110086824 | (20S,22E)-2-Methylene-19-Nor-22-Ene-1Alpha,25-Dihydroxyvitamin D3 - This invention discloses (20S,22E)-2-methylene-19-nor-22-ene-1α,25-dihydroxyvitamin D | 04-14-2011 |
20110105444 | ONCE-A-WEEK ADMINISTRATION OF 25-HYDROXY VITAMIN D3 TO SUSTAIN ELEVATED STEADY-STATE PHARMACOKINETIC BLOOD CONCENTRATION - An oral dosage form comprising a single dose of 25-hydroxy-vitamin D | 05-05-2011 |
20110112056 | Use of Carbon-2-Modified-Vitamin D Analogs to Induce the Formation of New Bone - It has been discovered that the 2-carbon-modified derivatives of 1α,25-dihydroxyvitamin D | 05-12-2011 |
20110124609 | Method of Preventing Type I Diabetes - The invention relates to novel methods of using 2α-methyl-19-nor-20(S)-1α,25-dihydroxyvitamin D | 05-26-2011 |
20110195941 | Methods of Use To Orally and Topically Treat Acne and Other Skin Conditions By Administering a 19-NOR Containing Vitamin D Analog With or Without a Retinoid - Oral and topical pharmaceutical compositions, kits and methods of treatment thereof for treating various skin disorder including acne, psoriasis, ichthyosis, photoaging, photodamaged skin, and, skin cancer. Exemplary vitamin D analogs as active pharmaceutical ingredients include 2-methylene-19-nor-20(S)-1α-hydroxy-bishomopregnacalciferol, 19-nor-26,27-dimethylene-20(S)-2-methylene-1α,25-dihydroxyvitamin D | 08-11-2011 |
20110237556 | (20S)-2-METHYLENE-19-NOR-22-DIMETHYL-1alpha,25-DIHYDROXYVITAMIN D3 AND (20R)-2-METHYLENE-19-NOR-22-DIMETHYL-1alpha,25-HYDROXYVITAMIN D3 - Compounds of formula I are provided where X | 09-29-2011 |
20110237557 | DIASTEREOMERS OF 2-METHYLENE-19-NOR-22-METHYL-1ALPHA,25-DIHYDROXYVITAMIN D3 - Compounds of formula I are provided where X | 09-29-2011 |
20110294764 | 2-METHYLENE-19,26-NOR-(20S)-1alpha-HYDROXYVITAMIN D3 - Compounds of formula I are provided where X | 12-01-2011 |
20120046252 | Calcium Formate for Use as a Dietary Supplement - A calcium formate composition for oral administration to an individual for the purpose of supplementary dietary calcium is disclosed. | 02-23-2012 |
20120071562 | 2alpha-Methyl-19-Nor-(20S)-1alpha-Hydroxy-Bishomopregnacalciferol and Its Uses - This invention discloses 2α-methyl-19-nor-(20S)-vitamin D analogs, and specifically 2α-methyl-19-nor-(20S)-1α-hydroxy-bishomopregnacalciferol and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also has little, if any, calcemic activity and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as renal osteodystrophy. This compound may also be used for the treatment or prevention of obesity. | 03-22-2012 |
20120083614 | (20R,25S)-2-Methylene-19,26-Dinor-1alpha,25-Dihydroxyvitamin D3 in Crystalline Form - A method of purifying (20R,25S)-2-methylene-19,26-dinor-1α,25-dihydroxyvitamin D | 04-05-2012 |
20120149669 | 22-Haloacetoxy-Homopregnacalciferol Analogs and Their Uses - This invention discloses 22-haloacetoxy-homopregnacalciferol analogs and specifically 22-bromoacetoxy-homopregnacalciferol and pharmaceutical uses therefor. This compound exhibits relatively little calcemic activity and does not promote cellular differentiation off HL-60 leukemia cells, but rather kills the cells. This cell death activity is found in small cell lung carcinoma also, but not in prostate cancer cells. This compound thus causes specific cell death in the absence of changes in calcium levels and without general toxicity in an animal. Therefore it might serve as a useful therapy for treatment of some forms of cancer, such as leukemia and lung cancer. | 06-14-2012 |
20120157418 | 2-Methylene-19-Nor-Vitamin D Analogs and Their Uses - This invention discloses 2-methylene-19-nor-vitamin D analogs, and specifically (20S)-25-hydroxy-2-methylene-19-nor-vitamin D | 06-21-2012 |
20120165300 | DIASTEREOMERS OF 2-METHYLENE-19-NOR-22-METHYL-1ALPHA,25-DIHYDROXYVITAMIN D3 - Compounds of formula I are provided where X | 06-28-2012 |
20120283227 | (20S)-24-(p-Toluenesulfonyloxy)-25,26,27-Trinorvitamin D3 Analogs and Their Uses - This invention discloses (20S)-24(p-toluenesulfonyloxy)-25,26,27-trinorvitamin D | 11-08-2012 |
20120283228 | 2alpha-Methyl and 2beta-Methyl Analogs of 19,26-Dinor-1alpha,25-Dihydroxyvitamin D3 and Their Uses - This invention discloses 2α-methyl and 2β-methyl analogs of 19,26-dinor-1α,25-dihydroxyvitamin D | 11-08-2012 |
20120322775 | 3-Desoxy-2-Methylene-19-Nor-Vitamin D Analogs and Their Uses - This invention discloses 3-desoxy-2-methylene-19-nor-vitamin D analogs, and specifically (20S)-3-desoxy-2-methylene-1α,25-dihydroxy-19-nor-vitamin D | 12-20-2012 |
20130005686 | 2-Methylene-(22E)-25-Hexanoyl-24-OXO-26,27-Cyclo-22-Dehydro-19-Nor-Vitamin D Analogs - This invention discloses 2-methylene-(22E)-25-hexanoyl-24-oxo-26,27-cyclo-22-dehydro-19-nor-vitamin D analogs, and specifically 2-methylene-(22E)-25-hexanoyl-24-oxo-26,27-cyclo-22-dehydro-19-nor-1α-hydroxyvitamin D | 01-03-2013 |
20130018021 | 2Alpha-Methyl and 2Beta-Methyl Analogs of 19,26,27-Trinor-(20S)-1Alpha-Hydroxyvitamin D3 and Their Uses - This invention discloses 2α-methyl and 2β-methyl analogs of 19,26,27-trinor-(20S)-1α-hydroxyvitamin D | 01-17-2013 |
20130053356 | 2-METHYLENE-19,23,24-TRINOR-1ALPHA-HYDROXYVITAMIN D3 - Compounds of Formula I are provided where R | 02-28-2013 |
20130053587 | Crystallization of 1alpha-Hydroxy-20-Methyl-2-Methylene-19,24,25,26,27-Pentanorvitamin D3 - A method of purifying 1α-hydroxy-20-methyl-2-methylene-19,24,25,26,27-pentanorvitamin D | 02-28-2013 |
20130073009 | METHOD OF TREATING MULTIPLE SCLEROSIS - A method and computer program product for suppressing the symptoms of multiple sclerosis (MS) by irradiating a subject exhibiting the symptoms with a predetermined dose of UV-containing light from a light source and detecting a suppression of the clinical symptoms of MS. In particular, the detected suppression of the clinical symptoms is disassociated from the vitamin D production within the subject. | 03-21-2013 |
20130090486 | Crystallization of 1alpha-Hydroxy-2-Methylene-18,19-Dinor-Homopregnacalciferol - A method of purifying 1α-hydroxy-2-methylene-18,19-dinor-homopregnacalciferol to obtain 1α-hydroxy-2-methylene-18,19-dinor-homopregnacalciferol in crystalline form using precipitation with hexane from ethyl acetate. A method of preparing 1α-hydroxy-2-methylene-18,19-dinor-homopregnacalciferol crystals acceptable for X-ray experiment using precipitation with hexane from benzene by diffusive exchange of the solvents is also described. | 04-11-2013 |
20130102567 | 3-Desoxy-2-Methylene-Vitamin D Analogs and Their Uses - This invention discloses 3-desoxy-2-methylene-vitamin D analogs, and specifically (20S)-3-desoxy-1α,25-dihydroxy-2-methylene-vitamin D | 04-25-2013 |
20130102573 | 2-METHYLENE-VITAMIN D ANALOGS AND THEIR USES - This invention discloses 2-methylene-vitamin D analogs, and specifically (20S)-25-hydroxy-2-methylene-vitamin D | 04-25-2013 |
20130102574 | 2-METHYLENE-VITAMIN D ANALOGS AND THEIR USES - This invention discloses 2-methylene-vitamin D analogs, and specifically (20S)-1α,25-dihydroxy-2-methylene-vitamin D | 04-25-2013 |
20130178449 | 2-Methylene-20(21)-Dehydro-19,24,25,26,27-Pentanor-Vitamin D Analogs - This invention discloses 2-methylene-20(21)-dehydro-19,24,25,26,27-pentanor-vitamin D analogs, and specifically 2-methylene-20(21)-dehydro-19,24,25,26,27-pentanor-1α-hydroxyvitamin D | 07-11-2013 |
20130253621 | Method for Treating Multiple Sclerosis - Methods and devices for suppressing clinical symptoms of multiple sclerosis (MS) by irradiating a subject exhibiting the symptoms with an effective dose of UV-containing light from a light source and detecting a suppression of the clinical symptoms of MS. In particular, the detected suppression of the clinical symptoms is disassociated from the vitamin D production within the subject. | 09-26-2013 |
20130295083 | 2a-Methyl-19-nor-(20S)-1a,25-dihydroxyvitamin D3 (2AMD) or 2 methylene-19-nor-(20S)-1a,25-dihydroxyvitamin D3 (2MD) Support Survival and Function of Transplanted Islet Cells In Type 1 Diabetes - A method of treating islet cell transplant patients is described herein. The method comprises the steps of a) identifying an islet cell transplant patient, b) treating the patient with 2AMD or 2AMD analog and c) observing a prolonged period of normal glycemia is disclosed. A composition for treatment of islet cell transplant patient is disclosed as well, wherein the composition comprises 50-400 ng/day of 2AMD or 2AMD analog. | 11-07-2013 |
20130324749 | Crystallization of (20R) and (20S) Analogs of 2-Methylene-19-Nor-24-Dimethyl-1alpha,25-Dihydroxyvitamin D3 - Disclosed are methods of purifying (20R) and (20S) analogs of 2-methylene-19-nor-22-dimethyl-1α,25-dihydroxyvitamin D | 12-05-2013 |
20130324750 | Crystallization of (20R)-2-Methylene-19-Nor-24-Difluoro-1alpha,25-Dihydroxyvitamin D3 - Disclosed are methods of purifying the compound (20R)-2-methylene-19-nor-24-difluoro-1α,25-dihydroxyvitamin D | 12-05-2013 |
20130324751 | Crystallization of (20R) 19-Nor-24-Difluoro-1alpha,25-Dihydroxyvitamin D3 - Disclosed are methods of purifying the compound (20R)-19-nor-24-difluoro-1α,25-dihydroxyvitamin D | 12-05-2013 |
20130324752 | Crystallization of (20R,22R)-2-Methylene-19-Nor-22-Methyl-1alpha,25-Dihydroxyvitamin D3 and Related Precursors - Disclosed are methods of purifying the compound (20R,22R)-2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D | 12-05-2013 |
20130331459 | A-Ring Modified 19-Nor-Vitamin D Analogs and Their Uses - Disclosed are 19-nor-vitamin D compounds, and specifically seco-A-2,19-dinor-1,25-dihydroxyvitamin D | 12-12-2013 |
20140005152 | Use of 2-Methylene-19-Nor-(20S)-1alpha,25-Dihydroxyvitamin D3 to Treat Secondary Hyperparathyroidism | 01-02-2014 |
20140011778 | 2-METHYLENE-19,23,24-TRINOR-1ALPHA-HYDROXYVITAMIN D3 - Compounds of Formula I are provided where R | 01-09-2014 |
20140018332 | METHODS OF USE TO ORALLY AND TOPICALLY TREAT ACNE AND OTHER SKIN CONDITIONS BY ADMINISTERING A 19-NOR CONTAINING VITAMIN D ANALOG WITH OR WITHOUT A RETINOID - Oral and topical pharmaceutical compositions, kits and methods of treatment thereof for treating various skin disorder including acne, psoriasis, ichthyosis, photoaging, photodamaged skin, and, skin cancer. Exemplary vitamin D analogs as active pharmaceutical ingredients include 2-methylene-19-nor-20(S)-1α-hydroxy-bishomopregnacalciferol, 19-nor-26,27-dimethylene-20(S)-2-methylene-1α,25-dihydroxyvitamin D | 01-16-2014 |
20140100203 | ONCE-A-WEEK ADMINISTRATION OF 25-HYDROXY VITAMIN D3 TO SUSTAIN ELEVATED STEADY-STATE PHARMACOKINETIC BLOOD CONCENTRATION - An oral dosage form comprising a single dose of 25-hydroxy-vitamin D | 04-10-2014 |
20140155360 | Calcium Formate for Use as a Dietary Supplement - A calcium formate composition for oral administration to an individual for the purpose of supplementary dietary calcium is disclosed. | 06-05-2014 |
20140187522 | Use of 2-Methylene-19-Nor-(20S)-1alpha,25-Dihydroxyvitamin D3 to Treat Secondary Hyperparathyroidism - Disclosed are methods of administering 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D | 07-03-2014 |
20140206655 | (22E)-2-METHYLENE-22-DEHYDRO-1ALPHA,24,25-TRIHYDROXY-19-NOR-VITAMIN D3 ANALOGS - Disclosed are (22E)-2-methylene-22-dehydro-1,24,25-trihydroxy-19-nor-vitamin D | 07-24-2014 |